New Partnerships Added to World Federation of Hemophilia Twinn…

COLLEGEVILLE, Pa., Apr. 17 /PRNewswire-AsiaNet/ –

Wyeth and Advocacy Community Mark Continued Commitment to
Patient Care on World Hemophilia Day

In honor of the twentieth Anniversary of World Hemophilia Day, Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE), together with the World
Federation of Hemophilia (WFH), announce the addition of five new
partnerships to the WFH Twinning Program. Begun in 1994, the Twinning Program
aims to increase the level of diagnosis and care for people with hemophilia
by pairing emerging treatment centers and patient organizations with more
established centers and organizations around the world. Wyeth has been the
sole corporate sponsor of the program since 2001, which now includes a total
of 31 partnerships worldwide.

"Wyeth recognizes that effective collaboration between advocacy
organizations and industry can help people with chronic illnesses such as
hemophilia," says Angela Rossetti, Assistant Vice President, and Global
Business Manager for Wyeth Hemophilia. "Our continued support of the Twinning
Program — now in its 16th year — and other advocacy initiatives is part of
a global collaborative effort designed to help patients with hemophilia and
their families receive access to better care."

The new Twinning partnerships include the following Hemophilia Treatment
Center Twins: Addis Ababa (Ethiopia) and Chapel Hill (North Carolina, USA);
Dakar (Senegal) and Paris (France); Quito (Ecuador) and Caracas (Venezuela);
Manipal (India) and Albuquerque, (New Mexico, USA); Skopje (Macedonia) and
Bonn (Germany). For more information on the Twinning Program and to view a
video of the Lima (Peru) and Fort Worth (Texas, USA) Twin in action, visit
www.wfh.org.

"World Hemophilia Day is an opportunity for all of us in the bleeding
disorders community to celebrate our achievements and raise awareness," said
Mark Skinner, WFH president. "The theme of this year’s World Hemophilia Day,
‘Together, we care’ embodies our spirit of collaboration to work together to
improve care for people with bleeding disorders. We are grateful to Wyeth for
its support of our programs, especially the Twinning Program, which play a
key role in achieving our vision of Treatment for All."

THE HEMOPHILIA COMMUNITY AND WYETH: A HISTORY OF PARTNERSHIP

Support of Children’s Camping Initiatives
For years, Wyeth has recognized the importance of the summer camp
experience to children in the bleeding disorders community. Since 1998, Wyeth
has been a major sponsor of Barretstown in Ireland — an innovative
recreational facility — where children with serious illnesses, including
children with hemophilia, can participate in a range of fun activities that
also are designed to promote self-confidence, independence, trust and coping
skills. In addition to its ongoing support, Wyeth works with Barretstown to
help run special camps for children with hemophilia.

Wyeth is also the founding and exclusive sponsor of NACCHO (North
American Camping Conference of Hemophilia Organizations). The annual NACCHO
conference is dedicated to the sharing of best practices for bleeding
disorder summer camps. Through NACCHO, children attending summer camp also
have the opportunity to participate in Leading Edge: Exploring the Outer
Limits, a nationally run adventure program that focuses on self-confidence
development for youth and adolescents in the bleeding disorders community.
Through its grants to NACCHO, Wyeth has supported 1,000 campers nationally,
and 500 campers internationally.

Wyeth-Sponsored Support Programs
Education and access to care are critical to the health and well-being of
patients with hemophilia. In addition to other initiatives that support the
bleeding disorders community, Wyeth proudly awards scholarships to deserving
students who have hemophilia. For the 2008-2009 academic year alone, Wyeth
awarded up to $100,000 to students with bleeding disorders seeking
collegiate, graduate and vocational degrees. Wyeth also works to help
patients with hemophilia maintain access to hemophilia therapy. Through its
Factor Resource Program, Wyeth provides services designed to assist patients
experiencing financial hardship or treatment access issues, including the
Insurance-Coverage Program and the Patient Assistance Program. Individuals
can get more information about these programs through the Wyeth Hemophilia
Hotline (1-888-999-2349).

Assisting Advocacy Organizations
Wyeth also provides assistance to numerous advocacy organizations and
their initiatives, including:

– WFH’s Global Alliance for Progress (GAP) program, a 10-year healthcare
development initiative to facilitate earlier and accurate diagnosis and
treatment of people with hemophilia and other bleeding disorders in
developing countries.
– National Hemophilia Foundation’s Campaign for Our Future, a program
designed to provide access to care for all members of the bleeding
disorders community.
– Hemophilia Federation of America’s Helping Hands program, which
provides emergency financial assistance for members of the bleeding
disorders community. Last year, Wyeth supported 122 families through its
grants to the Hemophilia Federation of America.
– Coalition for Hemophilia B, an organization that provides information
about treatment that will improve the quality of life of patients with
hemophilia B.
– International Society for Thrombosis and Haemostasis, which fosters and
advances science relating to the important medical problems of thrombosis
and abnormalities of haemostasis and vascular biology.

Wyeth and Hemophilia
Wyeth works to help improve the health of hemophilia patients through
education, patient assistance programs and by supporting associations
throughout the world. For more information on Wyeth and hemophilia, visit
www.hemophiliavillage.com, a comprehensive site that serves as a resource for
patients, parents, and caregivers in the hemophilia community.

About Wyeth Pharmaceuticals
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the
areas of women’s health care, infectious disease, gastrointestinal health,
central nervous system, inflammation, transplantation, hemophilia, oncology,
vaccines and nutritional products.

Wyeth is one of the world’s largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery, development,
manufacturing and marketing of pharmaceuticals, vaccines, biotechnology
products, nutritionals and non-prescription medicines that improve the
quality of life for people worldwide. The Company’s major divisions include
Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal
Health.

The statements in this press release that are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties include, among
others, risks related to our proposed merger with Pfizer, including
satisfaction of the conditions of the proposed merger on the proposed
timeframe or at all, contractual restrictions on the conduct of our business
included in the merger agreement, and the potential for loss of key
personnel, disruption in key business activities or any impact on our
relationships with third parties as a result of the announcement of the
proposed merger; the inherent uncertainty of the timing and success of, and
expense associated with, research, development, regulatory approval and
commercialization of our products and pipeline products; government
cost-containment initiatives; restrictions on third-party payments for our
products; substantial competition in our industry, including from branded and
generic products; emerging data on our products and pipeline products; the
importance of strong performance from our principal products and our
anticipated new product introductions; the highly regulated nature of our
business; product liability, intellectual property and other litigation risks
and environmental liabilities; the outcome of government investigations;
uncertainty regarding our intellectual property rights and those of others;
difficulties associated with, and regulatory compliance with respect to,
manufacturing of our products; risks associated with our strategic
relationships; global economic conditions; interest and currency exchange
rate fluctuations and volatility in the credit and financial markets; changes
in generally accepted accounting principles; trade buying patterns; the
impact of legislation and regulatory compliance; risks and uncertainties
associated with global operations and sales; and other risks and
uncertainties, including those detailed from time to time in our periodic
reports filed with the Securities and Exchange Commission, including our
current reports on Form 8-K, quarterly reports on Form 10-Q and annual report
on Form 10-K, particularly the discussion under the caption "Item 1A, Risk
Factors" in our Annual Report on Form 10-K for the year ended December 31,
2008, which was filed with the Securities and Exchange Commission on February
27, 2009. The forward-looking statements in this press release are qualified
by these risk factors. We assume no obligation to publicly update any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

SOURCE: Wyeth Pharmaceuticals

CONTACT: Media, Danielle Halstrom, Wyeth Pharmaceuticals
+1-484-865-2020

or Douglas Petkus, Wyeth
+1-973-660-5218

or Investors, Justin Victoria, Wyeth
+1-973-660-5340
(WYE)